Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H26O3 |
Molecular Weight | 326.4293 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(OC(=O)CC)C=C4
InChI
InChIKey=ROFBJLDRYQWJFI-WIRSXHRWSA-N
InChI=1S/C21H26O3/c1-3-20(23)24-14-5-7-15-13(12-14)4-6-17-16(15)10-11-21(2)18(17)8-9-19(21)22/h5,7,12,16-18H,3-4,6,8-11H2,1-2H3/t16-,17-,18+,21+/m1/s1
Estrone, the metabolite of estradiol, is used alone or in combination with other natural estrogens, in the form of ester (acetate, propionate~ or as hydrosoluble conjugate (sodium or piperazine sulphate) in the substitutive hormonal therapy (hypoestrogenic) and in the prevention of the bone loss in the cases of post-menopausal osteoporosis or in oophorectomized women.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 |
7.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Estrone Approved UseMenopausal hormone replacement therapy, Prophylaxis of osteoporosis |
|||
Primary | Estragyn Approved UseEstragyn Vaginal Cream is prescribed in the treatment of menopausal and post menopausal symptoms. |
Sample Use Guides
Oral
Menopausal hormone replacement therapy, Prophylaxis of osteoporosis
Adult: 1.4-2.8 mg daily in a cyclical or continuous regimen, usually given with estradiol and estriol. Cyclical progestogen should be given for 12-14 days of each cycle in women with intact uterus.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/913709
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54277166
Created by
admin on Sat Dec 16 08:33:15 GMT 2023 , Edited by admin on Sat Dec 16 08:33:15 GMT 2023
|
PRIMARY | |||
|
975-64-4
Created by
admin on Sat Dec 16 08:33:15 GMT 2023 , Edited by admin on Sat Dec 16 08:33:15 GMT 2023
|
PRIMARY | |||
|
1115H7M5RE
Created by
admin on Sat Dec 16 08:33:15 GMT 2023 , Edited by admin on Sat Dec 16 08:33:15 GMT 2023
|
PRIMARY | |||
|
m5033
Created by
admin on Sat Dec 16 08:33:15 GMT 2023 , Edited by admin on Sat Dec 16 08:33:15 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD